Expression of Prostate-Specific Membrane Antigen in Tumor-Associated Neovasculature of Renal Neoplasms

Baccala, Angelo A.; Sercia, Linda; Li, Jianbo; Heston, Warren D.W.; Zhou, Ming

doi:10.1016/j.urology.2007.03.025

Cited by 155 publications

(138 citation statements)

References 8 publications

Supporting

Mentioning

131

Contrasting

Unclassified

Order By: Relevance

“…[8][9][10][11][12] The functional role of endothelial PSMA is not known and, as recent studies demonstrated, endothelial PSMA expression can vary significantly within and between different tumor types. [12][13][14] Cyclooxygenase 2 (COX2) is a key enzyme in the arachidonic acid metabolism involved in the biosynthesis of prostagladins, which contribute to a pro-angiogenic microenvironment in tumors. 15 Expression of COX2 is upregulated in squamous cell carcinoma and treatment with COX2 selective inhibitors results in reduced tumor growth.…”

mentioning

confidence: 99%

High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity

et al. 2012

View full text Add to dashboard Cite

Prostate-specific membrane antigen (PSMA) is a transmembrane protein expressed in prostate cancer as well as in the neo-vasculature of nonprostatic solid tumors. Here, we determined the expression pattern of PSMA in the vasculature of oral squamous cell carcinoma. Using a previously validated antibody, PSMA staining distribution and cyclooxygenase 2 (COX2) expression status was evaluated in a cohort of patients with squamous cell carcinoma of the oral cavity (n ¼ 96) using immunohistochemistry and was correlated with clinicopathological features as well as outcome. Twenty-four (25%) cases showed no detectable PSMA staining, 48 (50%) demonstrated positive immunoreactivity for PSMA in less than 50% of microvessels and 24 (25%) cases showed strong endothelial PSMA expression in more than 50% of tumor-associated microvessels. High endothelial PSMA expression was associated with greatly reduced survival (18.2 vs 77.3 months; P ¼ 0.0001) and maintained prognostic significance after adjusting for grade and stage in multivariate analysis (hazard ratio ¼ 2.19, P ¼ 0.007). Furthermore, we observed a strong association between endothelial PSMA and cancer cell-specific COX2 expression. In conclusion, we provide the first evidence for the prognostic significance of endothelial PSMA expression in oral squamous cell carcinoma and, suggest a potential interaction between arachidonic acid metabolites and endothelial PSMA expression in the tumor neo-vasculature.

show abstract

mentioning

confidence: 99%

High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Daha nadir olarak akciğer, meme, kolorektal ve kütanöz melanom gelişme riski vardır. [15] Bizim olgumuzda iki taraflı BHK, prostat adenokanseri ve mesane kanseri tespit edilmiş olup bu durum Warren ve Gates'in senkron tümör kriterlerine uymaktadır.…”

Section: Discussionunclassified

Synchronous Bladder, Prostate and Bilateral Kidney Tumors, A Case Report

Demirkol¹,

Faydaci²,

Çelik³

et al. 2013

J Kartal TR

View full text Add to dashboard Cite

“…It is also expressed in RCC and many solid tumors with tumor neovascularization (39,40). PSMA is an exocrine expressed in the proximal tubule cells in normal kidney and to varying degrees in neovascular clear cell RCC (75%), chromophobe RCC (31%), oncocytoma (53%), and transitional cell carcinoma (21%) (40). PET imaging can be performed by binding PSMA to target molecules gallium (Ga)-68 or 18F.…”

Section: Gallium-68/18-fluorine Prostate-specific Membrane Antigen Pomentioning

confidence: 99%

“…Histopathologic evidence indicates that while PSMA uptake does occur in areas of neovascularization, uptake in the proximal tubules occurs not in the adjacent vascular structures, but rather in the tubule cells (42). Moreover, it has been shown that PSMA expression is lost in RCCs arising from proximal tubule cells that express PSMA (40). In another case series, 18F PSMA uptake was assessed in 5 patients.…”

Section: Gallium-68/18-fluorine Prostate-specific Membrane Antigen Pomentioning

confidence: 99%

Positron Emission Tomography in Renal Cell Carcinoma

Soydal¹,

Ürün²

2018

uob

View full text Add to dashboard Cite

IntroductionRenal cell carcinoma (RCC) is the most common solid kidney tumor. Contrast-enhanced computed tomography (CT) is the most frequently used imaging modality in the diagnosis, staging, and evaluation of recurrence and treatment response in patients with RCC. The overall success rate of CT for these indications is reported to be between 61% and 91% (1,2,3). However, as RCCs may appear isodense, hypodense, or hyperdense, it is difficult to distinguish benign and malignant renal masses by morphological methods (4). Magnetic resonance imaging (MRI) is recommended in cases where CT is contraindicated, such as patients who have contrast allergy or are pregnant. However, MRI is no more accurate than CT. This increases the importance of positron emission tomography (PET), which enables metabolic evaluation in addition to visualizing anatomic changes. In this review, we discuss currently available literature data regarding the use of PET applications with different radiopharmaceuticals in patients with RCC. Applications of Positron Emission Tomography in Renal Cell Carcinoma 18-Fluorine-Fluorodeoxyglucose Positron Emission TomographyPET is a metabolic imaging method that utilizes various positron-emitting radiopharmaceutical and can provide data on many different metabolic pathways. The most widely used radiopharmaceutical is a fluorodeoxyglucose molecule (FDG) labeled with 18-fluorine (18F). The modality is based on the principle of visualizing elevated glycolysis and glucose uptake in neoplastic tissues. Despite high success rates in many solid organ malignancies, the use of 18F-FDG for urinary system malignancies is limited due to excretion via the urinary tract. The first cases related to the use of 18F-FDG PET in RCC were described by Wahl et al. (5) in the early 1990s. The use of 18F-FDG PET in the detection of primary RCC is especially controversial (6,7,8,9,10). High and variable levels of background renal activity make it difficult to detect the primary focus. Forced diuresis with hydration may increase the sensitivity Renal cell carcinoma is the most common solid kidney tumor. Conventional methods such as computed tomography and magnetic resonance imaging are usually chosen for diagnosis, staging, and evaluating recurrence and treatment response. However, the sensitivity of these methods is limited in each indication. For this reason, metabolic evaluation with positron emission tomography has an important value in most solid tumors. However, the role of 18-fluorine-fluorodeoxyglucose (18F-FDG), which is the most commonly used positron emission tomography (PET) radiopharmaceutical, is limited in the evaluation of primary kidney lesions due to urinary excretion. Therefore, new radiopharmaceuticals with no or limited urinary excretion have been developed. In this paper, the application of PET imaging with the widely used 18F-FDG and the newly developed fluorothymidine and gallium-68/18F prostate-specific membrane antigen in renal cell carcinoma are reviewed.

show abstract

Expression of Prostate-Specific Membrane Antigen in Tumor-Associated Neovasculature of Renal Neoplasms

Cited by 155 publications

References 8 publications

High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity

High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity

Synchronous Bladder, Prostate and Bilateral Kidney Tumors, A Case Report

Positron Emission Tomography in Renal Cell Carcinoma

Contact Info

Product

Resources

About